Calls for papers
-
Mylan has announced that it has acquired “exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications” from Pfizer, along with “multi-dose dry powder inhaler technology.” The… Read more . . .
-
A study published online December 15, 2013 in Nature Medicine shows that mice allowed to become obese develop specific immune system changes leading to airway hyper-reactivity. Researchers at Boston Children’s Hospital found that mice fed… Read more . . .
-
FLUIDDA has announced that it will meet with the FDA on January 17, 2014 to present its Functional Respiratory Imaging (FRI) technology for screening respiratory drugs. The FDA is evaluating FRI as part of its… Read more . . .
-
Fresenius Kabi USA has announced the availability of 10 ml vials of 20% acetylcysteine inhalation solution. Acetylcysteine inhalation solution has been on the FDA’s drug shortage lists since 2011, in part due to a shutdown… Read more . . .
-
Asmacure has started enrolling patients for a Phase 2 trial of its ASM-024 inhalation powder in patients with moderate and severe COPD, the company has announced. The company said that it has also completed dosing… Read more . . .
-
DDL24 concluded on Friday, December 13 with a half day of presentations and the final exhibition session. Bo Olsson of AstraZeneca kicked off the morning with a talk titled, “Validation of a General In Vitro… Read more . . .
-
Retrophin has taken several steps toward development of intranasal oxytocin for the treatment of schizophrenia and autism, the company has announced. The biopharmaceutical company says that it will acquire Kyalin Biosciences and its lead product,… Read more . . .
-
The second day of DDL 24 opened with a posters on the podium session featuring the finalists for the 2013 Pat Burnell New Investigator Award. The six presenters were: Eva Faulhammer, Technical University, Austria: “Effect… Read more . . .
-
On day 1 of DDL 24, attendees gathered in the Pentland Auditorium of the Edinburgh International Conference Centre, where they were welcomed by conference chair Gary Pitcairn. In his opening remarks, Pitcairn noted that attendance… Read more . . .
-
GlaxoSmithKline has announced that it will invest approximately £200 million in UK manufacturing sites, including a new manufacturing facility in Ware for the Relvar Ellipta dry powder inhaler. The DPI was approved in Europe in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden